Zelgen to present promising oncology data at 2025 ESMO congress

Suzhou Zelgen Biopharmaceuticals will release new clinical data and updates for Alveltamig (ZG006) and Nilvanstomig (ZG005) at the ESMO annual congress from October 17-21, 2025. Alveltamig, a triple-specific antibody, showed promising efficacy in late-stage neuroendocrine carcinoma (NEC) and small cell lung cancer (SCLC).

In the ZG006-003 study for NEC, confirmed ORRs were 22.2% (10 mg Q2W) and 38.5% (30 mg Q2W), with DCRs of 33.3% and 65.4% respectively. For SCLC in the ZG006-001 study, confirmed ORRs reached 75.0% (10 mg Q2W), 60.0% (30 mg Q2W), and 91.7% (60 mg Q2W).

Nilvanstomig (ZG005), a PD-1/TIGIT bispecific antibody, in combination with etoposide and cisplatin (EP) for first-line late-stage NEC, demonstrated an ORR of 42.9% (10 mg/kg + EP) and 65% (20 mg/kg + EP). Disease control rates (DCR) for these groups were 85.7% and 100% respectively. Both drugs showed good safety and tolerability profiles in their respective trials.

The company stated that this announcement will not significantly impact its short-term performance, cautioning investors about the inherent risks in pharmaceutical development.